Tumor-related risk factors affect conversion of active surveillance to treatment for prostate cancer

Sumary of Tumor-related risk factors affect conversion of active surveillance to treatment for prostate cancer:

  • For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
  • Our study is the largest to assess the time to conversion from active surveillance to treatment for prostate cancer and provides new data on factors affecting the outcomes of this increasingly used management strategy.
  • Catalona, MD, Northwestern University Feinberg School of Medicine, Chicago Findings may help predict outcomes of active surveillance Active surveillance is used to monitor slow-growing, low-risk or localized prostate cancer rather than treating it straight away.
  • It typically involves regular prostate-specific antigen (PSA) screenings, prostate exams, imaging studies, and repeat biopsies to carefully monitor prostate cancer misclassification, growth, or progression without compromising long-term outcomes.
  • Active surveillance is increasingly viewed as the preferred approach for management of lower-risk prostate cancer.
  • Dr. Catalona and colleagues analyzed data on 6,775 patients with prostate cancer managed with active surveillance at 28 medical centers in a National Cancer Institute-sponsored Prostate SPORE (Specialized Program of Research Excellence) project (P50CA180995) study.
  • Sixty-eight percent of the men were classified as having low-risk disease, based on factors including the Gleason grade, which assess the aggressiveness of cancer cell behavior;
  • After adjustment for other factors, six cancer-related or clinical factors were independently related to shorter conversion times: higher Gleason grade, higher PSA level, higher tumor stage, and higher number of positive biopsy cores, more recent year of diagnosis, and younger age, confirming and expanding previous reports.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close